Genmab — November 2017
-
Totally agree E L. Especially as nothing changed during those 10 days. Anyway I am always very sceptical to target prices which are totally out of consensus with the rest of the market.
-
1st line approval will not change much Stockbull. It is 100% derisked of the analysts. Furthermore ALCYONE is not the important one. MAIA is the important. And you will have to wait to 2018 until you see MAIA related 1st line sales
-
Sorry.
You will have to wait to 2019 with MAIA sales!!! -
we are always waiting for some data and of course share price will increase when those milestones accomplished. Everybody expect that darzalex will sell for 7 B around 2022 but that does not mean that this sale is included in todays share price. Thus I think its realistic that we hit 1700kr when 1 line being approved in May 2018
-
You are far too optimistic. It will not happen.
-
Well in Q4-2016 everybody also said 1400 within 6 month was too optimistic and we hit 1488 in april 2017 so I thinl its realsisic with 1700 in April 2018 - also seen from the point of view that C20, DAX etc. increased +15% in 2017 and Genmab now underperforming compared to C20
-
The Dutch National Health Care Institute advising NOT to add daratumumab to the base Insurance package, unless price negotiations improve cost-effectiveness https://www.zorginstituutnederland.nl/publicaties/adviezen/2017/11/29/pakketadvies-daratumumab-darzalex-bij-multipel-myeloom
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind